Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults

References

• Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016;387(10027):1561–1572. doi: 10.1016/S0140-6736(15)00241-X
   PubMed Web of Science ®Google Scholar
• Nower L, Martins SS, Lin KH, et al. Subtypes of disordered gamblers: results from the national epidemiologic survey on alcohol and related conditions. Addiction. 2013;108(4):789–798. doi: 10.1111/add.12012
   PubMed Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–1203. doi: 10.1093/schbul/sby058
   PubMed Web of Science ®Google Scholar
• Fornaro M, Kardash L, Novello S, et al. Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective. Expert Opin Drug Discov. 2018;13(3):221–228. doi: 10.1080/17460441.2018.1428554
   PubMed Web of Science ®Google Scholar
• Michalak EE, Murray G, Young AH, et al. Burden of bipolar depression: impact of disorder and medications on quality of life. CNS Drugs. 2008;22(5):389–406. doi: 10.2165/00023210-200822050-00003
   PubMed Web of Science ®Google Scholar
• Mitchell PB, Goodwin GM, Johnson GF, et al. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008;10(1 Pt 2):144–152. doi: 10.1111/j.1399-5618.2007.00559.x
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. doi: 10.1111/bdi.12609
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Weisler RH, Townsend MH, et al. Bipolar II disorder: Current and future treatment options. Ann Clin Psychiatry. 2006;18(4):259–266. doi: 10.1080/10401230600948480
   PubMedGoogle Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777. doi: 10.2147/TCRM.S117321
   PubMed Web of Science ®Google Scholar
• García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J Clin Psychopharmacol. 2016;36(4):355–371. doi: 10.1097/JCP.0000000000000523
   PubMed Web of Science ®Google Scholar
• Li P, Zhang Q, Robichaud AJ, et al. Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. J Med Chem. 2014;57(6):2670–2682. doi: 10.1021/jm401958n
   PubMed Web of Science ®Google Scholar
• Snyder GL, Vanover KE, Zhu H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacol (Berl). 2015;232(3):605–621. doi: 10.1007/s00213-014-3704-1
   PubMed Web of Science ®Google Scholar
• Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: From novel pharmacology to clinical outcomes. Expert Rev Neurother. 2016;16(6):601–614. Erratum in: Expert Rev Neurother. 2016;16(6):v. doi: 10.1080/14737175.2016.1174577
   PubMed Web of Science ®Google Scholar
• Sleem A, El-Mallakh RS. Adaptive changes to antipsychotics: Their consequences and how to avoid them. Curr Psychiatry. 2022;21(7):46–50,52. doi: 10.12788/cp.0262
   Google Scholar
• Vanover KE, Davis RE, Zhou Y, et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): A positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology. 2019; 44(3):598–605. doi: 10.1038/s41386-018-0251-1.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64. doi: 10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Ginovart N, Kapur S. Role of dopamine D2 receptors for antipsychotic activity. Handb Exp Pharmacol. 2012;212:27–52. doi: 10.1007/978-3-642-25761-2_2
   PubMedGoogle Scholar
• Samaha AN, Seeman P, Stewart J, et al. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27(11):2979–2986. doi: 10.1523/JNEUROSCI.5416-06.2007
   PubMed Web of Science ®Google Scholar
• Yin J, Barr AM, Ramos-Miguel A, et al. Antipsychotic induced dopamine supersensitivity psychosis: a comprehensive review. Curr Neuropharmacol. 2017;15(1):174–183. doi: 10.2174/1570159x14666160606093602
   PubMed Web of Science ®Google Scholar
• Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330–340. doi: 10.1002/wps.20579
   PubMed Web of Science ®Google Scholar
• Citrome L, Saklad SR. Revisiting tardive dyskinesia: focusing on the basics of identification and treatment. J Clin Psychiatry. 2020; 81(2):TV18059AH3C. doi: 10.4088/JCP.TV18059AH3C.
   PubMed Web of Science ®Google Scholar
• Ali Z, Roque A, El-Mallakh RS. A unifying theory for the pathoetiologic mechanism of tardive dyskinesia. Med Hypotheses. 2020;140:109682. doi: 10.1016/j.mehy.2020.109682
   PubMed Web of Science ®Google Scholar
• Monsma FJ Jr, McVittie LD, Gerfen CR, et al. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature. 1989;342(6252):926–929. doi: 10.1038/342926a0
   PubMed Web of Science ®Google Scholar
• Seeman P, Nam D, Ulpian C, et al. New dopamine receptor, D2(Longer), with unique TG splice site, in human brain. Brain Res Mol Brain Res. 2000;76(1):132–141. doi: 10.1016/s0169-328x(99)00343-5
   PubMedGoogle Scholar
• Nakai S, Hirose T, Uwahodo Y, et al. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol. 2003;472(1–2):89–97. doi: 10.1016/s0014-2999(03)01857-0
   PubMed Web of Science ®Google Scholar
• Roberts RJ, Lohano KK, El-Mallakh RS. Antipsychotics as antidepressants. Asia Pac Psychiatry. 2016; 8(3):179–188. doi: 10.1111/appy.12186.
   PubMed Web of Science ®Google Scholar
• Wu HE, Okusaga OO. Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence. Psychiatr Q. 2015; 86(2):199–205. doi: 10.1007/s11126-014-9319-1.
   PubMed Web of Science ®Google Scholar
• Vanover KE, O’Gorman G, Correll CU, et al. Lumateperone (ITI-007): a novel investigational agent with broad therapeutic potential across multiple neuropsychiatric disorders. Eur Neuropsychopharmacol. 2017;27(Suppl 4):S660–S661. doi: 10.1016/S0924-977X(17)31234-8
   Google Scholar
• Titulaer J, Radhe O, Danielsson K, et al. Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism. Eur Neuropsychopharmacol query. 2022;62:22–35. doi: 10.1016/j.euroneuro.2022.06.009
   PubMed Web of Science ®Google Scholar
• Bourne JA. SCH 23390: The first selective dopamineD1-like receptor antagonist. CNS Drug Rev. 2001;7(4):399–414. doi: 10.1111/j.1527-3458.2001.tb00207.x
   PubMedGoogle Scholar
• Hare BD, Shinohara R, Liu RJ, et al. Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects. Nat Commun. 2019;10(1):223. doi: 10.1038/s41467-018-08168-9
   PubMedGoogle Scholar
• Desormeaux C, Demars F, Davenas E, et al. Selective activation of D1 dopamine receptors exerts antidepressant-like activity in rats. J Psychopharmacol. 2020;34(12):1443–1448. doi: 10.1177/0269881120959613
   PubMed Web of Science ®Google Scholar
• Sørensen A, Ruhé HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review. Mol Psychiatry. 2022;27(1):192–201. doi: 10.1038/s41380-021-01285-w
   PubMed Web of Science ®Google Scholar
• Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020 Jul 22;107(2):234–256. doi: 10.1016/j.neuron.2020.06.002.
   PubMed Web of Science ®Google Scholar
• Jones GH, Vecera CM, Pinjari OF, et al. Inflammatory signaling mechanisms in bipolar disorder. J Biomed Sci. 2021 Jun 11;28(1):45. doi: 10.1186/s12929-021-00742-6.
   PubMed Web of Science ®Google Scholar
• Dutheil S, Watson LS, Davis RE, et al. Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation. J Neurosci. 2023:43(5):863–877. doi: 10.1523/JNEUROSCI.0984-22.2022
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: A phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178(12):1098–1106. doi: 10.1176/appi.ajp.2021.20091339
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Durgam S, Huo J, et al. The efficacy of lumateperone in patients with bipolar depression with mixed features. J Clin Psychiatry. 2023;84(3):22m14739. doi: 10.4088/JCP.22m14739
   PubMedGoogle Scholar
• McIntyre RS, Durgam S, Kozauer SG, et al. The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses. Eur Neuropsychopharmacol. 2023;68:78–88. doi: 10.1016/j.euroneuro.2022.12.012
   PubMed Web of Science ®Google Scholar
• Suppes T, Durgam S, Kozauer SG, et al. Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial. Bipolar Disord. 2023 Feb 13. (Epub ahead of print). doi: 10.1111/bdi.13310
   PubMed Web of Science ®Google Scholar
• Tohen M, Dugam S, Kozauer S, et al. Long-term lumateperone treatment in bipolar disorder: Six-month open-label extension study. CNS Spectr. 2023;28(2):233–233. doi: 10.1017/S1092852923001591
   Google Scholar
• Shah B, Elsayed OH, El-Mallakh RS. The foundational role of mood stabilizers in the treatment of bipolar disorder. Curr Psychiatry. 2023;22(5):35–41. doi: 10.12788/cp.0346
   Google Scholar
• Sleem A, El-Mallakh RS. Advances in the psychopharmacotherapy of bipolar disorder type I. Exp Opin Pharmacother. 2021;22(10):1267–1290. doi: 10.1080/14656566.2021.1893306
   PubMed Web of Science ®Google Scholar
• Rhee TG, Olfson M, Nierenberg AA, et al. 20-Year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry. 2020;177(8):706–715. doi: 10.1176/appi.ajp.2020.19091000
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Ghaemi SN, Sagduyu K, et al. STEP-BD Investigators. Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord. 2008;111(2–3):372–377. doi: 10.1016/j.jad.2008.03.025
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Vöhringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. J Affect Disord. 2015;184:318–321. Erratum in: J Affect Disord. 2016 Jan 15;190:895. doi: 10.1016/j.jad.2015.04.054
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Doroodgar M, Elsayed OH, et al. The serotonin theory of depression. Mol Psychiatry. 2023 Jun 16. Epub ahead of print. doi: 10.1038/s41380-023-02091-2
   PubMed Web of Science ®Google Scholar